8-K: Tevogen Bio Holdings Inc. Stockholders Elect Directors and Ratify Auditor at 2025 Annual Meeting

Tevogen Bio Holdings Inc. announced the successful election of two Class I directors and the ratification of KPMG LLP as its independent registered public accounting firm at its 2025 Annual Meeting of Stockholders.

Summary

• Tevogen Bio Holdings Inc. held its 2025 Annual Meeting of Stockholders on June 23, 2025.
• As of the record date, April 30, 2025, there were 183,893,433 shares of common stock outstanding and entitled to vote.
• A quorum was met with 167,360,586 shares of common stock represented in person or by proxy.
• Stockholders elected Jeffrey Feike and Dr. Curtis Patton as Class I directors to serve for a term of three years each.
• Jeffrey Feike received 150,304,146 votes For, 652,203 Against, 14,742 Abstentions, and 16,389,495 Broker Non-Votes.
• Dr. Curtis Patton received 150,313,660 votes For, 647,811 Against, 9,620 Abstentions, and 16,389,495 Broker Non-Votes.
• Stockholders ratified the appointment of KPMG LLP as the company's independent registered public accounting firm for the fiscal year ending December 31, 2025.
• The ratification of KPMG LLP received 167,188,556 votes For, 92,456 Against, 79,574 Abstentions, and 0 Broker Non-Votes.

Sentiment

Score: 7

Explanation: The sentiment is positive as all proposals passed successfully with strong shareholder support, indicating stable corporate governance and no apparent dissent or issues.

Positives

• Both proposed Class I directors, Jeffrey Feike and Dr. Curtis Patton, were successfully elected with overwhelming majority votes.
• The appointment of KPMG LLP as the independent registered public accounting firm was ratified with strong stockholder support.
• A significant quorum of 167,360,586 shares was achieved, indicating strong stockholder engagement.

Future Outlook

The document primarily reports on past voting results and does not contain explicit forward-looking statements or guidance beyond the appointment of the auditor for the current fiscal year.

Management Comments

• Ryan Saadi, Chief Executive Officer, signed the report on behalf of Tevogen Bio Holdings Inc.

Industry Context

This 8-K filing is a routine disclosure of annual meeting results, common across all publicly traded companies. It reflects standard corporate governance practices, including the election of directors and the ratification of the independent auditor, which are fundamental requirements for maintaining transparency and accountability to shareholders.

Comparison to Industry Standards

• The successful election of directors and ratification of the auditor with high 'For' votes aligns with typical outcomes for routine proposals at annual general meetings across the industry, indicating stable corporate governance.
• The quorum achieved (over 91% of outstanding shares represented) is robust and generally exceeds the average participation rates seen in many public company annual meetings, suggesting strong shareholder engagement for Tevogen Bio Holdings Inc.

Management Changes

Corporate Governance

Stakeholder Impact

• Shareholders: Their votes determined the composition of a portion of the Board and the appointment of the auditor, directly impacting corporate oversight and financial transparency.
• Management: The CEO's signature on the filing indicates formal reporting of the meeting outcomes.

Next Steps

• The elected Class I directors, Jeffrey Feike and Dr. Curtis Patton, will serve for a term of three years each.
• KPMG LLP will serve as the independent registered public accounting firm for the fiscal year ending December 31, 2025.

Key Dates

Keywords

Tevogen Bio Holdings Inc., TVGN, SEC filing, 8-K, Annual Meeting, Stockholders, Director Election, KPMG LLP, Auditor Ratification, Corporate Governance, Nasdaq Stock Market